David Granville, PhD, FAHA
Professor, Pathology and Laboratory Medicine, University of British Columbia
Associate Director, BC Professional Firefighters’ Burn and Wound Healing Group, UBC
Principal Investigator, International Collaboration On Repair Discoveries (iCORD)
Principal Investigator, UBC Centre for Heart Lung Innovation
Co-Founder and Chief Scientific Officer, viDA Therapeutics Inc.
Dr. Granville is a Professor in Pathology and Laboratory Medicine at the University of British Columbia (UBC), Vancouver, Canada. He is also a Principal Investigator at the International Collaboration On Repair Discoveries (ICORD) Centre and Associate Director of the BC Professional Firefighters’ Burn and Wound Healing Group. His early work at QLT (Vancouver, BC) supported the development and FDA approval of Visudyne®, the first treatment for age-related macular degeneration, the leading cause of blindness in the elderly. In 2001, Dr. Granville relocated to the Scripps Research Institute (La Jolla, CA), where his research identified a novel therapeutic approach for attenuating ischemia and reperfusion injury that led to the formation of Radical Therapeutix Inc (San Diego, CA). In 2003 he was recruited back to UBC. While at UBC, he has received several prestigious awards including a Canada Research Chair, Canada Top 40 Under 40, Michael Smith Foundation Scholar and in 2014 was inducted as a Scholar of the Royal Society of Canada. His research is presently focused on the role of immune-secreted proteases in autoimmune and/or chronic inflammatory disorders of the skin and blood vessels. This work has led to the startup of viDA Therapeutics of which he serves as a co-Founder and Chief Scientific Officer.